 AUSTIN, Texas, Oct. 6, 2021 PRNewswire -- Natera, Inc. NASDAQ: NTRA, a leader in improving patient outcomes through genetic and cell-free DNA cfDNA testing, announced the completion of the VALID Study Validation for Allograft Lungs Implementing Donor-derived cell-free DNA for ProsperaTM in lung transplant recipients. This clinical validation study has been accepted as a late-breaking abstract for presentation at the American College of Chest Physicians ACCP international online meeting, CHEST 2021, to be held on October 1720, 2021. 